Telomir Pharmaceuticals Clinical Trial Data
Telomir Pharmaceuticals announced the publication of peer-reviewed preclinical data in the International Journal of Molecular Sciences demonstrating that Telomir-Zn restored visual function and retinal structure in a model of age-related macular degeneration (AMD). The study showed that 14 days of oral treatment significantly improved visual performance, reduced mitochondrial oxidative stress, and increased telomeric DNA content. While the company remains focused on its Phase 1/2 clinical trial for triple-negative breast cancer, these findings suggest the drug's metal-dependent epigenetic biology may have broader applications beyond oncology.